Wednesday, March 24, 2021 3:29:38 PM
$NBIO officially opened its Phase I trial to evaluate Pritumumab, the Company's lead Monoclonal Antibody therapeutic asset, as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases. https://finance.yahoo.com/news/nascent-biotech-opens-phase-1-120000666.html
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
